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A B S T R A C T
Most of the cancer deaths could be avoided by early detection of the tumor when it is conﬁned to its primary site
and it has not metastasized. To this aim, one of the most promising strategies is the discovery and detection of
protein biomarkers shed by the young tumor to the bloodstream. Proteomic technologies, mainly mass spec-
trometry and multiplexed immunoassays, have rapidly developed during last years with improved limits of
detection and multiplexing capability. Unfortunately, these developments together major investments and large
international eﬀorts have not resulted into new useful protein biomarkers. Here, we analyze the potential and
limitations of current proteomic technologies for detecting protein biomarkers released into circulation by the
tumor. We ﬁnd that these technologies can hardly probe the deepest region of the plasma proteome, at con-
centrations below the pg/mL level, where protein biomarkers for early cancer detection may exist. This clearly
indicates the need of incorporating novel ultrasensitive techniques to the proteomic tool-box that can cover the
inaccessible regions of the plasma proteome. We here propose biological detectors based on nanomechanical
systems for discovery and detection of cancer protein biomarkers in plasma. We review the modes of operation
of these devices, putting our focus on recent developments on nanomechanical sandwich immunoassays and
nanomechanical spectrometry. The ﬁrst technique enables reproducible immunodetection of proteins at con-
centrations well below the pg/mL level, with a limit of detection on the verge of 10 ag/mL. This technology can
potentially detect low abundance tumor-associated proteins in plasma at the very early stages of the tumor. The
second technique enables the identiﬁcation of individual intact proteins by two physical coordinates, the mass
and stiﬀness, instead of the mass-to-charge ratio of the protein constituents. This technology enormously sim-
pliﬁes the identiﬁcation of proteins and it can provide useful information on interactions and posttranslational
modiﬁcations, that otherwise is lost in mass spectrometry.
1. Introduction
Cancer is a leading cause of death globally. The World Health
Organization (WHO) estimates that approximately nine million people
die of cancer every year [1,2]. Most of these lives could be saved if
patients had timely access to early detection. The tumor at early stage is
localized at the organ of origin and can be easily resected. In addition,
treatments are more eﬃcacious. Unfortunately, tumor at early stages
use to be asymptomatic. At later stages the tumor invades surrounding
tissue and metastasizes to distant organs. When metastasis occurs, it
creates complications that account for the vast majority of deaths from
cancer [3]. Without early detection, treatment costs rise substantially,
resources are used ineﬃciently and the need for palliative care services
increases.
Cancer initiation and progression is regarded as a multi-step pro-
cess, which is reﬂected by progressive genetic alterations that drive the
transformation of normal human cells into highly malignant derivates
[4]. Mutations, ampliﬁcations or deletions in these genes may lead to a
de-coupling of biological mechanisms involved in the regulation of
normal cell growth and diﬀerentiation. These changes are reﬂected into
alterations in the gene and protein expression patterns of the tumor
cells. Identiﬁcation of the genetic and proteomic modiﬁcations asso-
ciated to cancer, referred to as cancer biomarkers, is crucial for detec-
tion of the disease, choice of the optimal therapy and more precise
prognostication of disease progression [5,6]. Nucleic acid biomarkers
include gene mutations, gene methylation, gene overexpression and
chromosomal aberrations. Despite the increasingly reﬁned technologies
for discovery of nucleic acid biomarkers, biomarkers for early cancer
detection still have not been found. A fundamental reason for this
disparate progress is that the gene expression is not always correlated
with the actual abundance of proteins, the functional components
within the organism. Compared to nucleic acids, proteins reﬂect more
precisely the physiological state of cells and tissues. Therefore, research
on cancer biomarker discovery is increasingly turning its attention on
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the discovery of protein biomarkers [7,8]. Another fundamental reason
for this change of target is that a signiﬁcant part of the proteins of every
cell of the body is released to the blood stream through several me-
chanisms. In addition, blood is the sample of choice for medical diag-
nosis because of its easy accessibility and the complete laboratory in-
frastructure already developed for its analysis.
Discovery of protein biomarkers shed by the tumor at early stages in
plasma could be the key for early cancer detection. Unfortunately, we
are still far from achieving this chimera. Proteomic technologies,
mainly mass spectrometry and multiplexed immunoassays, have de-
veloped rapidly during recent years with improved limits of detection
and multiplexing capability. Unfortunately, these developments to-
gether major investments and large international eﬀorts have not re-
sulted into new useful protein biomarkers. A fundamental reason for
this dismal progress is the extraordinary complexity of the human
plasma that comprises more than 10 000 protein species with known
concentrations ranging more than 10 orders of magnitude [9,10]. It is
expected that biomarkers for early cancer detection are well-below the
bottom of the current detection limits in proteomics. Although, the
analytical capability of proteomic technologies is rapidly improving, we
foresee the need of new ultrasensitive technologies that can access to
the deepest part of the human plasma proteome.
Nanotechnology has provided in the last decade a wide variety of
nanobiosensors that have shown ultrahigh sensitivity with small vo-
lumes of sample. The unprecedented sensitivity of these biosensors is
capitalized by the reduction of the size of the sensing structures, and by
the appearance of new phenomena at the nanoscale. Nanobiosensors
raised large interest in the biomedical community for their potential to
surpass the limitations of contemporary technologies to quantitate
biomarkers at concentrations well-below the pg/mL level [11]. How-
ever, the promises of most of these technologies have not been trans-
lated into valid clinical tests. Many nanobiosensors have shown mul-
tiple pitfalls and issues regarding speciﬁcity, reproducibility and
reliability. The time has arrived that research on nanosensors faces the
real problems that arise in the long and uncertain path from the proof of
concept up to achieving an assay of clinical utility. Detecting ultralow
concentrations of biomolecules in complex mixtures poses a formidable
challenge that requires of solving manifold problems including non-
speciﬁc adsorption, biological noise and the diﬀusion limit [12–14].
We here review recent advances in biological detectors based on
nanomechanical systems that can revolutionize the discovery and de-
tection of low-abundance protein cancer biomarkers in plasma.
Nanomechanical systems are suspended micro- or nanoscale structures
in which their position and motion is sensitively altered by minuscule
forces such as the weak interactions between a pair of biomolecules
[15,16]. Biological detectors based on nanomechanical systems exploit
this exquisite sensitivity to translate biological signals into the me-
chanical domain [17–22]. Although these technologies have still not
been used in clinical proteomics, we envision that their unique and
unprecedented attributes make them promising candidates for tackling
early cancer detection the next years. In order to see how nano-
mechanical systems can complement current eﬀorts in proteomics, we
will start the review by describing the existing knowledge about the
human plasma proteome and protein biomarkers as well as the em-
ployed technologies to discover protein biomarkers in plasma. Then we
will review recent advances on nanomechanical biological detectors
that can contribute to the discovery of new protein biomarkers in
plasma.
2. Human plasma proteomics
Human proteomics aims to identify and quantify all the proteins
expressed by∼20,300 human protein-coding genes predicted from the
human genome and their corresponding protein isoforms [23]. In
comparison to genomics, proteomics has advanced at much slower rate.
Genomics rapidly progressed due to its powerful biotechnological
arsenal that includes synthesis of nucleic-acid probes, methods for
ampliﬁcation of few copies in complex mixtures and the development
of constantly reﬁned technologies for nucleic acid sequencing. Unlike
DNA, which is subject to one major form of modiﬁcation (methylation),
proteins are more complex structures that undergo various types of
post-translational modiﬁcations such phosphorylation, acetylation and
glycosylation— each of which is capable of producing a functional shift
that potentially aﬀects disease development, progression and ther-
apeutic response. Moreover, no methods exist for protein synthesis,
ampliﬁcation nor sequencing. Only until very recently, proteomic
technologies based on mass spectrometry and antibody arrays have
been able to provide reliable information about the human proteome.
In 2014, ﬁrst drafts of human proteome were described based on ana-
lysis of mass spectrometry data [24,25]. Later, in depth analysis of these
publicly available drafts has shown signiﬁcant pitfalls that led to an
overestimation of the identiﬁed protein-coding genes [26]. The for-
midable complexity of deciphering the human proteome led to the
launch of large-scale international initiatives such as the human pro-
teome project (HPP) by the Human Proteome Organization's (HUPO)
[27]. In 2015, one of the primary HPP information resources, the
Human Proteome Atlas programme, presented the ﬁrst map of the
human tissue proteome [28]. About 38% of the genes encode both se-
creted and membrane-bound proteins. This fraction of the proteome is
particularly interesting as aberrant secretion or shedding of membrane-
bound proteins with an extracellular domain is a fundamental me-
chanism by which these proteins can be elevated in blood at early
stages of a tumor [5]. A classic example is the cell membrane protein
HER2, whose overexpression is associated with high risks of relapse and
death from breast and ovarian cancers. HER2 is the target of ther-
apeutic monoclonal antibody trastuzumab. In 2000, the US Food and
Drug Administration (FDA) approved a blood test for measuring cir-
culating levels of HER2 for monitoring patients with metastatic breast
cancer. Currently, it is estimated than roughly 15% of the predicted
proteins by the human genome are still unidentiﬁed [29]. These
missing proteins can be also a valuable source of future cancer bio-
markers.
Plasma proteome represents the most comprehensive subproteome
for discovery of biomarkers for early cancer detection [9,10]. It harbors
proteins secreted or released from almost all tissues, along with proteins
derived from infectious organisms and parasites residing inside the
body. Every cell in the body leaves a record of its physiological state in
the products it sheds to the blood [7]. Thus, the goal of early cancer
detection is to ﬁnd in blood tumor products that can be used as un-
ambiguous signatures of the development of a tumor in some part of the
body. The comprehensiveness of the plasma proteome, together its easy
accessibility and simple collection, makes plasma the body ﬂuid of
choice for future screening tests for cancer diagnosis. Unfortunately,
our existing knowledge about the human plasma proteome remains
very incomplete. Currently, we know that approximately 99% of the
plasma comprises 22 highly-abundant proteins including albumin (that
makes up 55%), immunoglobulins, transferrin and haptoglobin [9,10].
The concentration of the highly-abundant proteins ranges from
∼10 μg/mL to∼10 mg/mL. The remaining 1% is estimated to contain
more than 10,000 proteins, including tissue-derived proteins (e.g.
clinically used cancer biomarkers) in the ng/mL range and cytokines
and interleukins in the low pg/mL range. The wide dynamic range of
plasma proteins, at least 10 orders or magnitude, as well as the het-
erogeneity and complexity of plasma, makes plasma the most diﬃcult
sub-proteome to characterize.
The Plasma Proteome Database (PPD, http://www.
plasmaproteomedatabase.org/) was developed as a part of Human
Proteome Organization's (HUPO) initial eﬀort to characterize human
plasma proteome [10]. The PPD contains data of the plasma protein
concentration for 1278 proteins (Fig. 1). We observe that the number of
identiﬁed proteins increases as the concentration approaches to 1 ng/
mL, and then abruptly declines for lower concentrations. This change of
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trend in the number of discovered proteins is a clear manifestation of
the technological limitations for characterizing the plasma proteome at
concentrations well-below the ng/mL level.
Proteomic technologies have rapidly developed during recent years
with improved limits of detection and multiplexing capability. These
technologies can be split into two categories: mass-spectrometry-based
technologies and multiplexed immunoassays. Fig. 2 shows the con-
tribution of these technologies to our existing knowledge on the protein
concentration in plasma (PPD). This graph reﬂects the state-of-the-art
in plasma proteomics. Clearly, mass-spectrometry techniques dominate
the discovery of plasma proteins, representing the 88% of the PPD
entries. However, the number of proteins detected by mass-spectro-
metry quickly falls for concentrations below 1 ng/mL, whereas im-
munoassay methods enable to quantitate proteins in plasma up to near
the pg/mL level. We below analyze the power and limitations of these
technologies.
2.1. Mass spectrometry-based technologies
The generic overall process for identiﬁcation and quantiﬁcation of
proteins using mass spectrometry (MS) [30–36] is sketched in Fig. 3(a).
Proteins are ﬁrst digested to peptides by sequence-speciﬁc enzymes
such as trypsin. The resulting peptide mixture is separated by high-
performance liquid chromatography (HPLC) that is on-line coupled to
an electrospray- ionization (ESI) needle to convert the peptides into gas-
phase peptide ions that are introduced into the vacuum of the mass
spectrometer. However, most highly resolving HPLCs are unable to
separate the tens to hundreds of thousands of diﬀerent peptide species
generated by the digestion, and thus many peptides will co-elute from
the column and co-ionize simultaneously. This eﬀect largely aﬀects the
performance characteristics of the MS data-acquisition strategies [35].
The mass-to-charge (m/z) ratios of the peptides are obtained at high
resolution by ion trap mass analyzers such as Orbitrap hybrids or
quadrupole time-of-ﬂight (TOF). Peptide identiﬁcation requires its
fragmentation by dissociation methods such as collision-induced dis-
sociation or electron-transfer dissociation. Peptide identity is derived by
computational methods from the combined information of the m/z
spectra of the precursor peptide (MS spectra) and of the corresponding
fragment ions (MS/MS spectra). The computational methods compare
the data with predictions calculated for each possible linear peptide
Fig. 1. Plasma protein concentration for the 1287 proteins reported in the
PPD (http://www.plasmaproteomedatabase.org/). The inset shows the
number of proteins reported per log of concentration. The dashed line
approximately represents the lowest concentration at which our knowl-
edge on the plasma proteome becomes to decline. Red symbols indicate
FDA-approved protein tumor markers for blood tests, which are described
in Table 1. (For interpretation of the references to colour in this ﬁgure
legend, the reader is referred to the web version of this article.)
Fig. 2. Contribution of the two main classes of proteomic technologies to
the quantiﬁcation of proteins in plasma. Data source: PPD (http://www.
plasmaproteomedatabase.org/).
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sequence and provide the most likely peptide identity.
Two general types of MS-based proteomics approaches are widely
used for biomarker-related applications: global quantitative proteomics
for biomarker discovery and targeted quantitative proteomics for can-
didate biomarker veriﬁcation. We brieﬂy review the two most im-
portant acquisition methods used in these approaches. We refer the
reader to the many excellent review papers about MS-based proteomics
for a more comprehensive survey of other signal acquisition methods
that are gaining importance [31,33–36].
Global proteomics or shotgun proteomics uses data-dependent ac-
quisition (DDA) that provides an unbiased and complete coverage of the
proteome (Fig. 3b). In DDA, MS spectra of the precursor peptides are
obtained, which result in a three dimensional map of the intensity
versus m/z and HPLC separation time. The instrument operates in
iterative acquisition cycles of about 1 s of the MS spectra and MS/MS
spectra [34,35]. MS/MS spectra is only performed for each precursor
for a single time point after precursor signal is above a certain
threshold. The relative protein abundances can be determined by
comparing signal intensity or peak area of corresponding peptides.
However, the capability for quantiﬁcation is poor because the ioniza-
tion eﬃciency is dependent of the peptide sequence. In addition, the
ionization eﬃciency of the peptides is modiﬁed when peptides enter ion
source at the same time in a process called ion suppression. Quantiﬁ-
cation can be improved by sample labelling with diﬀerent stable iso-
topes or by spiking isotopically label forms of the peptides of interest.
The strength of the DDA method is the capability for routine detection
of thousands of proteins, being the method of choice for uncovering
complex proteomes and discovery of candidate protein biomarkers.
However, DDA-based MS has inherent low reproducibility. For in-
stance, automated precursor selection at a given chromatographic re-
tention time introduces certain randomness due to variability in the
chromatographic separation. Another major limitation is the under-
sampling due to the limited MS sampling duty cycle, which provides
missing data, especially of the low abundance proteins.
Among the MS methods for targeted quantitative proteomics, we
here highlight the selected reaction monitoring (SRM) [37,38] that was
named method of the year 2012 by the journal Nature Methods [39]. In
the SRM method, no complete MS/MS spectra are acquired (Fig. 3b).
Fig. 3. Schematics of MS-based proteomics and data-acquisition strategies. (a) Outline of the generic workﬂow in MS-based plasma proteomics. At the top, the sample preparation process
is shown. Plasma proteins are digested and the resulting mixture of peptides are separated by HPLC and introduced in the mass spectrometer by ESI. At the bottom, the sequential process
events undergone by each peptide ion in the mass spectrometer are shown. The peptide ions are guided by ion optics to the ﬁrst mass analyzer that provides the mass-to-charge ratio (m/
z), then they are fragmented and the fragments are measured in a second mass analyzer. The data obtained in the ﬁrst and second mass analyzers are referred to as MS spectrum and MS/
MS spectra, respectively. (b) Structure of the data in the MS and MS/MS spectra in: the data-dependent acquisition mode used for shotgun proteomics (top) and the selected-reaction
monitoring acquisition mode for quantitative targeted proteomics (bottom).
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Rather, a set of discrete predetermined fragment ion signals is re-
peatedly recorded for each predeﬁned peptide over time [35,40]. The
combinations of precursor m/z and fragment ion m/z pairs (typically
three to ﬁve per peptide) are termed transitions. The lists of transitions
are predeﬁned in the acquisition method. Therefore, prior knowledge
about the identity of the targeted peptides and of their fragmentation
characteristics is required. The technique is best applied for consistently
quantifying or validating the presence of targeted proteins, rather than
discovering new peptides/proteins. SRM is typically performed on a
triple quadrupole (QQQ) MS instrument where Q1 and Q3 serve as
precursor ion and fragment ion ﬁlters, respectively, and Q2 acts as
collision cell [34,36]. SRM is designed to achieve precise and accurate
quantiﬁcation (i.e., actual protein concentration) of the proteins by
comparing signals with those of reference isotope-labeled synthetic
peptides spiked in known amounts in the sample.
Mass spectrometry analysis of blood-derived plasma or serum poses
a signiﬁcant challenge in terms of sensitivity and analytical depth.
Shotgun mass spectrometry has been the tool of choice for plasma
proteomics due to its capability for identiﬁcation of a large set of pro-
teins with no prior knowledge required. However, quantiﬁcation ac-
curacy and reproducibility remain as limiting factors. Precursor selec-
tion in shotgun mass spectrometry analysis is biased towards the more
abundant proteins in the plasma (concentrations above 1 μg/mL).
Reducing the complexity of protein by depletion of the most abundant
proteins enables identiﬁcation of proteins at concentrations of
1–100 ng/mL. The counterbalancing problem is the inadvertent re-
moval of other proteins, which could be due to peptides and proteins
bound to the high-abundance proteins, especially albumin; cross-re-
activity with the antibodies used for depletion of the high-abundance
proteins; or non-speciﬁc binding to the used column or resin or dye
[41]. Targeted mass spectrometry based on SRM is exclusively hy-
pothesis driven, and thus it requires of the previous identiﬁcation of the
plasma proteome components by shotgun proteomics. It is focused on
the detection and quantiﬁcation of protein biomarkers previously de-
tected in shotgun proteomics. In contrast with shotgun proteomics, MS
based on SRM yields precise measurements of the protein concentra-
tions with very low coeﬃcients of variation and high reproducibility
[42]. When applied to the plasma without any further depletion/en-
richment step, SRM can achieve limits of detection of 0.1–1 μg/mL
[36]. By applying depletion/enrichment steps, the limit of detection is
at the ng/mL level. The fact that relatively few predetermined peptides
(∼10) are targeted per analysis constitutes the biggest strength (con-
sistent quantiﬁcation) but also the biggest limitation of the method.
Advances in instrumentation are providing mass spectrometers with
higher scan speed and dynamic range. This enables new modes in data
acquisition workﬂows such as the data-independent acquisition (DIA),
which aims to acquire MS/MS spectra of all precursor peptides in the
sample that are above the detection limit of the instrument [35,36].
This strategy promises to overcome the undersampling limitations of
DDA used for shotgun proteomics and the limited number of peptides
analyzed by SRM. This huge amount of data can be achieved by opening
the precursor isolation window that breaks the “one MS/MS spec-
trum = one peptide” dogma of DDA and SRM. The technology oﬀers a
quantiﬁcation accuracy similar to SRM with slightly worse sensitivity.
The complexity of the data makes still challenging the high-throughput
quantiﬁcation of proteins in plasma [43]. Foreseeable advances in in-
strumentation and bioinformatics will have high impact in this acqui-
sition mode.
2.2. Antibody-based plasma proteomics
Antibody-based proteomics [44–47] harness the extraordinary
capability of the immune system to produce antibodies that recognize a
unique molecule, referred to as antigen, of pathogens. Antibody-antigen
recognition is based on spatial complementarity (lock and key) of the
variable antigen-binding region of the antibody and a particular region
of the antigen (epitope). The forces involved in this lock-and-key me-
chanism are weak interactions including electrostatic forces, hydrogen
bonds, hydrophobic interactions and van der Waals forces. It has been
estimated that humans generate about 1010 diﬀerent antibodies (Abs),
each capable of binding a distinct epitope of an antigen. Since the
human proteome consists of approximately 20,500 non-redundant
proteins, is feasible to foresee that multiplexed immunoassays is a
powerful strategy to explore the proteome.
Antibodies can be produced by several methods, each having its
advantages and disadvantages [47,48]. Polyclonal antibodies (pAbs)
are generated by injection of the antigen/adjuvant conjugate to an
animal of choice to initiate an ampliﬁed immune response. pAbs are
heterogeneous, which allows them to bind to a wide range of epitopes
of the target protein. However, the speciﬁcity of these antibodies is in
many cases very low and it varies from batch to batch. Alternatively,
monoclonal antibodies (mAbs) are made by identical immune cells that
are all clones of a unique parent cell (e.g. cell culture that involves
fusing myeloma cells with mouse spleen cells immunized with the de-
sired antigen). Monoclonal antibodies are speciﬁc to a single epitope of
the target protein. Another option is recombinant antibodies (rAbs)
based on phage display technology. This technology involves re-
covering antibody genes from source cells, amplifying and cloning the
genes into an appropriate phage vector, introducing the vector into a
host (bacteria, yeast, or mammalian cell lines), and achieving expres-
sion of adequate amounts of functional antibody. Unlike polyclonal and
monoclonal antibodies (mAbs), rAbs do not need hybridomas and an-
imals in the production process. rAbs display many beneﬁcial features
for generation of antibody arrays, such as representing a renewable
antibody source, the antibody library can be designed on a molecular
level to display desired features and, very importantly, rAbs are very
reproducible [48,49]. In fact, reproducibility of the antibodies has be-
come a crucial problem as it is estimated that only a small percentage of
commercial antibodies actually show required performance in terms of
speciﬁcity [48,50]. Several online catalogues have been created in
order to provide a valuable resource of antibodies. For instance, anti-
bodypedia is a searchable database of more than 1,800,000 antibodies
covering 94% of the protein-encoding genes that provides information
on the eﬀectiveness of speciﬁc antibodies in speciﬁc applications [50].
Enzyme-linked immunosorbent assay (ELISA) remains the gold
standard for measuring protein concentration in human plasma
[46,47,50,51]. ELISAs can be performed with a number of modiﬁca-
tions to the basic procedure. The key step, immobilization of the an-
tigen of interest, can be accomplished by direct adsorption to the assay
plate or indirectly via a capture antibody (cAb) that has been attached
to the plate. The antigen is then detected either directly by an enzyme-
tagged detection antibody (dAb) or indirectly by an enzyme-tagged
secondary antibody that recognizes the detection antibody. The ELISA
sandwich assay format provides higher speciﬁcity and sensitivity. In the
ﬁnal step, the enzyme substrate is added to produce a change of color of
the surface that is used as the detection signal. Depending of the an-
tigen, the limit of detection of ELISA typically ranges from 0.001 to
0.1 ng/mL and the dynamic range is from 2 to 3 logs. Based on ELISA,
multiplexed immunoassays have been developed to quantify multiple
antigens in a single sample of human plasma. These methods oﬀer the
advantage over MS-based proteomics of high sensitivity without frac-
tionation or depletion of high-abundance proteins.
Multiplexed immunoassays for serum proteomics can be classiﬁed
based on the solid support used for antibody immobilization: planar
microarrays, in which cAbs are discretely immobilized on planar sub-
strates (e.g. glass slides or microtitre plates) and antibody suspension
bead arrays (SBAs) in which the cAbs are discretely immobilized in
ﬂuorescently coded microbeads [47,50–52]. In both formats, readout of
the immunoassays is typically performed by measuring the ﬂuorescence
intensity of the immunoreaction tags. Fluorescent labelling formats can
be split into direct and indirect labelling methods. In the ﬁrst method,
the sample proteins are tagged with ﬂuorescent labels, thus avoiding
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the need of dAbs that recognize a free region of the immunocaptured
protein [52]. The direct labelling method allows detection of hundreds
of proteins with a limit of detection of ∼ng/ml. However, this tech-
nology is prone to nonspeciﬁc adsorption that gives rise to false posi-
tives and low reproducibility. The indirect labelling method is similar to
ELISA sandwich assay, using ﬂuorescently tagged dAbs for speciﬁc
binding to the antigen recognized by the capture antibodies. The use of
two speciﬁc antibodies per protein largely enhances the reproducibility,
speciﬁcity and sensitivity. However, this method requires of the optimal
identiﬁcation of compatible antibody pairs with minimal cross-re-
activity. Cross reactivity arises from the nonspeciﬁc binding between
capture antibodies, detection antibodies and proteins [53]. It is esti-
mated that the probability of cross-reactions scales up with the square
of targets. In general, cross-reactivity contributes to an increase of the
background noise, degrading the limit of detection and, in the worst
cases, generating false positive signals. This limits the multiplexing
capability to tens of proteins. A schematic of the indirect labelling
method and cross-reactivities in antibody microarrays and SBAs is
shown in Fig. 4.
Immobilization of capture antibodies in planar microarrays is per-
formed by continuous ﬂow microspotter systems and other advanced
array printing technologies. However, the optimal recognition cap-
ability of these antibody microspots is compromised by denaturation of
the antibodies due to drying of the microdroplets, inhomogeneous
surface density and uncontrolled conformation of the antibodies. These
eﬀects, if uncontrolled, can lead to signiﬁcant inter-assay variability.
Nonetheless, antibody microarrays are suitable for large production and
automated readout, which enables high-throughput analysis. In SBAs,
the sample is mixed with plastic microbeads labeled with diﬀerent
ﬂuorescent IDs and functionalized with capture antibodies. After all the
incubation and washing steps, the microbeads are individually analyzed
by a ﬂow cytometry system, which features a dual-laser system to de-
tect bead/captured protein ID. The bead array setup surmounts some of
the limitation of planar arrays, such as printing artefacts and mass-
transport limitations, which are abrogated by the conduction of the
immunoassay in a liquid phase whereby the proteins are not denatured
and the immunoreaction kinetics is improved, as agitation is readily
executed. Currently, SBA constitutes the prevailing technology for FDA-
approved multiplex protein analysis in clinical settings.
In addition to planar microarrays and bead assays, several strategies
have been developed for addressing the cross-reactivity limit for mul-
tiplexing such as the use of aptamers instead of antibodies [54],
proximity ligation assays in which the antibodies are tagged with DNA
barcodes [55] or spatially localizing the immunoreaction steps [56], to
name a few. These strategies reduce the cross-reactivity at the expense
of a more complex and lengthy process.
2.3. Where the biomarkers for early cancer detection are?
Despite the large international eﬀorts and major investments made
over the last two decades for discovery of cancer protein biomarkers,
only few biomarkers have been approved by the US Food and Drug
Administration (FDA) for blood tests [57–61]. These biomarkers, re-
presented as red dots in Fig. 1 are described in Table 1. Most of this
handful of FDA approved biomarkers are not useful for early cancer
detection [5,41,60]. Nonetheless, they are useful for monitoring disease
evolution, response to therapy and recurrence of disease [6]. The rea-
sons for this dismal progress are manifold including low reproducibility
of the proteomics technologies, lack of quality standardization of the
samples and misinterpretation by the bioinformatics tools of the big
data generated by proteomics. These factors have made that most of
recently proposed biomarkers fail when they are validated for clinical
Fig. 4. Schematics of the indirect labelling method in Ab planar microarrays and Ab suspension bead arrays. The starting point for both multiplexed immunoassay formats is the plasma
sample extracted from blood. Ab planar microarrays can be obtained by robotically printing cAbs upon an activated surface slide. SBAs employ plastic microbeads infused with a single
(or several) chemiluminescent/ﬂuorescent dyes and a functionally activated surface, prior to linking with a speciﬁc cAb. Beads functionalized with the same cAb have a unique
ﬂuorescent signature for subsequent identiﬁcation by ﬂow cytometry. Both multiplexed formats comprise similar steps to ELISAs: incubation with the sample, washing, incubation with
the dAbs, washing and readout of the signal. Unlike ELISA, the dAbs are tagged with ﬂuorescent molecules and readout is performed by ﬂuorescent detection methods. SBAs feature the
advantage that all the immunoassay steps are carried out in a ﬂow chamber which enhances the immunoreaction kinetics and avoids Ab denaturation due to drying as it may occurs in
planar microarrays. Both multiplexed immunoassay formats suﬀer from the cross-reactivity problem. Possible cross-reactions are labeled as CR. CR1 = Cross-reaction of a cAb with a
noncognate protein. CR2 = Cross-reaction of a dAb with a noncognate protein. CR3 = Cross-reaction between a dAb and a cAb.
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use [61]. The diﬃculty for ﬁnding biomarkers for early cancer detec-
tion reﬂects the lengthy and diﬃcult path from biomarker discovery to
clinical validation, and the lack of well-deﬁned pipelines for this pro-
cess.
In addition to the diﬃculties mentioned above, tumor-derived
proteins in the circulation are at ultralow concentrations (< 1 pg/mL)
during the early stages of tumor development. Current proteomic
technologies are blind to these concentration levels buried by a com-
plex mixture of more than 10,000 proteins, some of them at con-
centrations 11 orders of magnitude higher. Given that tumor-derived
proteins are present at higher concentrations closer to their source, a
logical route to discover protein biomarkers with current technologies
is to detect cancer-associated proteins in the tumor tissue and proximal
ﬂuids. However, this approach does not guarantee the discovery of
early cancer biomarkers that can be screened by simple blood-tests.
Proteins found in the tumor can be unstable in circulation, associated
with other proteins and subject to post-translational modiﬁcations.
Moreover, the protein expression at the tissue level may not correlate
with the relative concentration in blood. For instance, although PSA
gene transcription is downregulated in prostate cancer, PSA protein
levels in blood increase at early stages from 0.5–2 ng/mL to 4–10 ng/
mL due to the destruction of the tissue architecture. In addition, cancer
is a multistep disease that progresses through various phases resulting
from the accumulation of genetic aberrations. The cancer biomarkers at
early stages may not be the same as those at advanced stages, where
most of the biopsies are taken.
Fig. 5 shows an estimation of the protein levels in plasma as a
function of the tumor size, time after genesis of initial tumor cell and
protein copies per cell. The calculation is based on recent reports aimed
to quantify the proteome at the single cell level in mammalian and
human cells [62–64]. These works estimate that the number of proteins
per cell is of about 2–3 × 109, comprising protein copies from 10 up to
107, with a typical median value of 104. In most of the cells, 1000 most
highly expressed proteins make up about 90% of the cell proteome. We
assume a protein mass of 44 kDa that is the mean value in mammalian
cells. We assume that the tumor growth follows a Gompertz function
that has successfully described the growth of solid tumors [64,65]. In
this model, we use a tumor-doubling time of 77 days and decaying rate
of 2.5 × 10−4 day−1. These values are similar to those found in
ovarian carcinoma. We assume that 10% of the proteins enter into the
vasculature, similar to the secretion of CA-125 in ovarian carcinoma.
For the sake of simplicity, we assume that the protein concentration in
plasma reﬂects the concentration in cells. A more realistic model should
account for the diverse mechanisms of protein elevation and elimina-
tion in plasma. However, this estimation is only intended to show the
current technology limits and what can be expected by implementing
recent ultrasensitive technologies.
In our model, the tumor reaches a size (diameter) of 20 mm 10 years
after its genesis. These values are similar to those considered critical for
initiation of metastasis [66,67]. We assess the capability of current
techniques, MS and immunoassays, for detecting potential protein
biomarkers shed by the tumor to the bloodstream. The limit of detec-
tion of these techniques is of about 1 ng/mL and 1 pg/mL, respectively.
If the tumor markers are proteins highly expressed (> 106 copies), the
tumor could be detected by MS with a size of about 12 mm, 9 years
after its beginning, whereas immunoassays could detect the tumor with
a size of 1 mm, ﬁve years after its beginning. In the case of intermediate
expressed proteins, the tumor could be detected by MS and im-
munoassays with a size of about 50 mm and 5 mm, 12.5 and 7.5 years
after its genesis, respectively. Low abundance proteins at the level of
100 copies per cell can only be detected by immunoassays, but more
than 10 years after its genesis. So far, clinically approved protein bio-
markers are found in the plasma at concentrations of ng/mL. With some
notable exceptions, this protein repertoire is not useful for early cancer
detection. The current technological limits prevent exploring the dee-
pest part of the plasma proteome that arises from low abundant pro-
teins in the tumor tissue. We here analyze the potential of nano-
mechanical systems for detecting ultralow concentration of proteins in
plasma. For instance, as reviewed below, immunoassays based on na-
nomechanical systems are capable of detecting 50 ag/mL of protein
biomarkers in plasma with very high repeatability [68,69]. This sensi-
tivity implies that high abundance, intermediate abundance and low
abundance proteins shed by the tumor could be detected in plasma
when the tumor size is 50, 200 and 800 μm, respectively, at least ﬁve
years before metastasis may occur. At this stage, most of the cancers can
be eﬃciently treated and cured.
3. Nanomechanical systems for biomarker discovery
Current proteomics technologies cannot identify and detect proteins
in plasma at concentrations below the pg/mL level. The deepest region
of the plasma proteome is likely to contain proteins that can be used as
future cancer biomarkers for early detection and population screening.
It becomes clear that the development of ultrasensitive technologies for
exploring the plasma proteome is demanding. Here, we describe recent
advances on biodetection techniques based on nanomechanical systems
Table 1
List of FDA-approved protein tumor makers used in clinical blood tests. The term “monitoring” stands for monitoring: disease status, disease progression, response to therapy. *Estimation
of the concentration as the concentration is indirectly measured in ELISA in enzymatic units per volume unit. **Cut-oﬀ concentration depends on the concentration of fPSA and total PSA.






CEA (carcinoembryonic Ag) Colorectal Monitoring ≈5 1965 1985
PSA (Prostate-speciﬁc Ag. PSA may be free or
bound to other proteins)
Prostate Monitoring 4–10 1979 1986
AFP(alfa-fetoprotein) Testicular Ovarian
Hepatocellular
Monitoring 10–200 1963 1992
fPSA(free PSA) Prostate Diagnosis < 0.1 [PSA] 1995 1997
TG Thyroglobulin Thyroid Monitoring ≈1 1956 1997
CA-27–29 Breast Monitoring ≈1–10* 1989 1997
CA-15-3 Breast Monitoring ≈1–10* 1984 1997
CA-125 Ovarian Monitoring ≈20 1981 1997
HER2 Breast Monitoring HER2 positive
tumor
≈15 1991 2000
CA-19-9 Pancreatic Monitoring ≈1–10* 1979 2002
AFP-L3 (AFP isoform) Hepatocellular Diagnosis in patients with
liver disease
≈30 1986 2005
FDP (Fibrin/ﬁbrinogen degradation products) Colorectal Monitoring ≈600 1990 2008
HE4 (human epididymis protein) Ovarian Monitoring ≈0.3-0.4 ng/mL 2003 2008
Pro2PSA (PSA precursor isoform) Prostate Diagnosis > f([fPSA],[tPSA])** 2001 2012
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that promise in the near future to complement the arsenal of proteomic-
technologies.
3.1. Biosensors based on nanomechanical systems
Nanomechanical systems (NMSs) are devices that comprise a micro-
or nanosized moving part whose natural oscillation frequency and po-
sition are sensitive to mechanical perturbations such as external forces
and adsorption of substances. NMSs can be routinely fabricated by well-
established processes in microelectronics, which guarantee mass pro-
duction with highly reproducible features and low cost. NMSs shaped as
microcantilevers are the most widespread devices by a conjunction of
manifold reasons including simplicity, well-known theoretical models
to interpret their response, low compliance and the capability for po-
sitioning the free end near the place of interest [70,71]. Micro-
cantilevers are usually fabricated in silicon or silicon nitride with
lengths from 100 to 500 μm, widths from 10 to 100 μm and thicknesses
from 0.1-1 um (Fig. 6(a)). These devices can be miniaturized up to
achieving suspended silicon nanowires, at least one million times
lighter than standard microcantilevers (Fig. 6(b)) [72,73]. As shown
below, reduction of the device dimensions is directly translated into an
improvement of the detection limits. Large arrays with hundreds of
devices can be easily fabricated for high throughput analysis and par-
allelization (Fig. 6(c)) [74]. NMSs shaped as doubly-clamped beams,
trampolines and drums, to name a few, have been also used, although in
less extent.
Biological detectors based on NMSs, referred to as nanomechanical
biosensors, aim to measure the properties of biological components and
their interactions in the mechanical domain [17–22]. Nanomechanical
biosensors relies on measuring changes in the deformation (displace-
ments) and vibrational properties of NMSs when adsorption of biomo-
lecules or biomolecular interactions take place on the NMS surface
[17]. The displacements of the nanomechanical system range from
angstroms to hundreds of nanometers. These displacements can be
measured by optical techniques such as the beam deﬂection method
and interferometry that can provide detection limits well-below
0.01 nm Hz−1/2. Electrical methods for the displacement readout can
also be used although the sensitivity is reduced. Nanomechanical bio-
sensors can be operated in the static or dynamic mode depending on
whether the deformation or the vibration of the NMS is measured, re-
spectively (Fig. 7). In the static mode, the displacement of the NMS,
namely a microcantilever, is measured in real-time with a typical
Fig. 5. Mathematical prediction of the plasma concentration of proteins
shed by the tumor as a function of the time and protein abundance in the
tumor cells. The relation between the time after the tumor inception and
the tumor size is modeled by a Gompertz function. Parameters used in the
model: plasma volume = 3490 mL, protein mass = 44 kDa, cell
volume = 3000 μm3, tumor volume to tumor cell volume = 4.5, tumor
doubling time = 77 days, tumor decaying rate = 2.5 × 10−4 day−1, ratio
of protein biomarkers in plasma to protein biomarker in the tumor
cells = 0.1.
Fig. 6. Scanning electron microscopy images of
several micro- nanocantilever sensors. (a) Silicon
microcantilevers, 500 μm long, 100 μm wide and
1 μm thick. (b) Suspended silicon nanowires an-
chored to the wall of a microtrench. The length is of
about 6 μm and the diameter of about 150 nm (c)
Two dimensional array of silicon nitride cantilevers
with a length of 60 μm, a width of 15 μm and
thickness of 100 nm.
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averaging time of a second (Fig. 7(a)). The static mode is used for
measuring biomolecular interactions in buﬀer solution on the surface of
the NMS. A biological layer is conﬁned to one of the faces of the NMS,
called active face. The molecular interactions within the biomolecular
components (electrostatic forces, hydrogen bonding, conformational
entropic interactions, hydrophobic interactions) of the layer gives rise
to surface stress [75–80]. The diﬀerence between surface stress of the
active face and opposite face (passive face) induce the bending of the
NMS.
In the dynamic mode, a NMS is driven to oscillate near or at the
fundamental resonance frequency and variations of the amplitude or
phase lag are monitored [17] (Fig. 7(b)). Phase-lock loops (PLLs) are
usually implemented for keeping constant the phase lag and hence
monitoring the resonance frequency in real-time. NMSs operated in the
dynamic mode are usually referred to as nanomechanical resonators.
Measuring in the time or frequency domains has the added advantage of
not requiring calibration of the displacement measurements as it occurs
in the static mode. Calibration of the static signal is a source of un-
certainty. The dynamic mode has been traditionally used for mass
sensing. The concept is that the resonance frequency of a NMS down-
shifts upon biological adsorption by an amount that is proportional to
the ratio between the added mass and the NMS mass. Rapid advance-
ments in micro- and nanofabrication technologies have allowed re-
searchers to miniaturize the resonators to achieve increasingly smaller
mass detection limits [17]. Mass records rapidly evolved from GDa
(mass of Escherichia coli), achieved with a microcantilever in 2001 [81]
to Da (10−24 g; the proton mass), achieved with a suspended carbon
nanotube in 2012 [82]. The best detection limits have been obtained in
high-vacuum conditions because the friction between the NMS and the
environment is negligible, which implies better resolution in the re-
sonance frequency measurement. Translation of these achievements to
liquids, the natural environment for biology, remains elusive because of
the very high energy loss in viscous environments [83,84]. When the
thickness of the biomolecules is comparable to the thickness of the
NMS, the stiﬀness of the biomolecules comes into play inducing an
increase of the resonance frequency [71,85–87]. As shown below, this
major complexity for interpreting the resonance frequency shifts can be
converted into an opportunity for identiﬁcation of biomolecules.
The choice among the static and dynamic measurement modes de-
pend on the dominant mechanical signal in the biological assay, i.e.,
intermolecular forces, mass changes or stiﬀness variations. In some
applications, the static and dynamic modes can be combined providing
richer information on the biomolecular interactions. However, the op-
timal design of the NMS to achieve a highly sensitive static signal is
diﬀerent from the optimal design for obtaining a highly sensitive dy-
namic signal. Thus, a compromise in the design must be achieved. In
addition, the simultaneous detection of the static and dynamic signal
requires of specialized displacement measurement methods that avoid
cross-talk between static and dynamic signals [88].
3.2. Methods for protein detection based on nanomechanical systems
In analogy to proteomics technologies, nanomechanical biodetec-
tion methods can be split into two broad categories: aﬃnity-based
methods and spectrometry methods. Aﬃnity-based methods makes use
of antibodies for detecting the target proteins, and hence requires prior
knowledge on the expected protein content of the sample. Aﬃnity
based methods can be split into label-free assays and sandwich assays.
Nanomechanical spectrometry identiﬁes the target proteins by their
physical properties. Depending on the signal processing algorithms,
NMS properties and measurement method, nanomechanical spectro-
metry can be split into mass and mass and stiﬀness spectrometry.
Nanomechanical spectrometry distinguishes itself from nanomecha-
nical aﬃnity assays in its potential for unbiased analysis of protein
content.
3.2.1. Nanomechanical label-free aﬃnity assays
This approach is based on the static mode method. The active face of
a compliant microcantilever is coated with antibodies against the target
proteins. The opposite passive face is blocked with antifouling mole-
cules to minimize nonspeciﬁc adsorption. The surface stress induced by
the antibody-antigen binding induces the microcantilever displacement
that is detected by either optical or electrical methods. The measure-
ments can be performed in real-time [76,77,89,90] or, alternatively,
before and after incubation of the microcantilever in the test sample to
perform end-point detection of the target proteins [12]. Detection in
real time provides information about the kinetics of the biomolecular
interactions, while end-point detection is usually deemed more prac-
tical for applications where the need is limited to detecting the presence
of a protein and its concentration. Endpoint detection is also more
suitable for multiplexing. Label-free nanomechanical aﬃnity assays
attracted worldwide attention at the beginning of new millennium due
to its capability for detection of sub-ng/mL concentrations of biomo-
lecules with no need of labels for quantiﬁcation. Despite worldwide
huge eﬀorts, the promise of applications of this technology in the bio-
medical ﬁeld has been frustrated because of its low reproducibility.
With some notable exceptions, works lack of both thorough statistical
analysis and appropriate validation methods that are widely use in
standard immunoassays to assess robustness, precision, limit of detec-
tion, limit of quantiﬁcation, inter- and intra-assay variability, se-
lectivity, probability of false positives and false negatives, etc [12].
Related to these problems is the mechanism of generation of the na-
nomechanical signal. Intermolecular forces due to molecular recogni-
tion are weak, and the induced surface stress signal can be in most of
the cases buried by nonspeciﬁc signals such a nonspeciﬁc adsorption,
small variations in the environmental conditions (temperature, pH, etc)
and instrumental artefacts (thermal drift). More importantly, the gen-
eration of detectable amounts of cantilever deﬂection requires highly
crowded surfaces in order to maximize the repulsive physical steric
Fig. 7. Schematic of the most common operation modes of nanomechanical biosensors
exempliﬁed with a microcantilever. (a) In the static mode, one side of the cantilever is
functionalized for immobilizing a monolayer of biomolecules. As the biomolecules form a
monolayer, the cantilever bends due to the intermolecular forces parallel to the canti-
lever. (b) In the dynamic mode, the cantilever is driven by piezoelectric actuators,
magnetic forces, and light-induced forces, to name a few. When a biomolecule lands on
the cantilever, the resonance frequency shifts downwards due to the added mass.
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interactions, ion osmotic pressure and hydration forces [17,79]. These
conditions are diﬃcult to obtain in a reliable way. The label-free cap-
ability of aﬃnity nanomechanical biosensors is remarkable and can be
harnessed for studying biomolecular interactions without the pertur-
bative eﬀect of tags. However, this class of nanomechanical biosensor
has limited capability for human proteomics.
3.2.2. Nanomechanical sandwich immunoassays
This method is based on the dynamic mode described above. The
surface of the NMS is functionalized with capture antibodies. The
functionalized NMS is ﬁrst incubated with the sample to allow binding
of the targeted protein biomarker to the capture antibodies immobilized
on the NMS surface. Second, after stringent rising of the NMS to remove
nonspeciﬁc adsorption, the NMS is incubated with a solution of nano-
particles, usually gold nanoparticles, functionalized with the detection-
antibodies that recognize a free region of the captured biomarker. The
NMS is rinsed and dried. The nanoparticle acts as a mass label. The
resonance frequency of the NMS is measured before and after the im-
munoassay in air or vacuum. The mass of the nanoparticles induces a
signiﬁcant downshift of the resonance frequency. This method allows
counting the number of nanoparticles on the surface of the NMS. The
use of two antibodies together the advantageous features of the dy-
namic mode, largely enhance the selectivity, reproducibility and the
limit of detection. In 2009, Craighead and co-workers successfully used
this method with trampoline-like NMSs for detecting PSA in serum,
achieving a detection limit of 0.05 pg/mL [91]. In 2014, Kosaka and
collaborators used arrays of microcantilevers and 100-nm diameter
gold nanoparticles for detection of the cancer biomarkers PSA and CEA
in serum [69] (Fig. 8). A detection limit of 10−4 pg/ml was achieved
with both biomarkers, which is at least ﬁver orders of magnitude lower
than that achieved in routine clinical practice. The implications of this
ultrasensitivity in early cancer detection are discussed above (Fig. 5 and
related text). Kosaka’s method oﬀers an added advantage: the micro-
cantilevers can be used as optical cavities that boost the light scattered
by the gold nanoparticles (a process known as cavity-enhanced plas-
monic transduction). Simple inspection of the microcantilevers by a
simple optical microscope in the dark-ﬁeld mode allows distinguishing
the presence of ultralow concentration of biomarkers in the sample.
Combining nanomechanical and nanooptical quantiﬁcation in a single
device provides major robustness (two eyes are better than one) and
higher reliability, achieving rates of false positives and false negatives
in controlled samples of ∼10−3. Reﬁnement of the technology has al-
lowed detection of 10−5 pg/mL of the HIV-1 capsid antigen p24 in
human serum [68]. The technique was adapted to the common medical
diagnostic format by carrying the immunoassay steps in a 96-well mi-
crotiter plate format, which allows detection of multiple samples in the
same plate. The technology is also suitable for high degree of paralle-
lization and to detect multiple biomarkers by using dense microarrays
of microcantilevers and dedicated microﬂuidics [74].
3.2.3. Nanomechanical mass spectrometry
In 2012, nanomechanical resonators were used for the ﬁrst time for
real-time mass spectrometry of proteins [92,93]. Similarly to MS, the
species were introduced by either electrospray ionization or matrix-
assisted laser desorption ionization (MALDI). Subsequently, the ionized
species are guided by ion optics to the nanomechanical resonator in
high vacuum (<10−5 Torr). As each analyte adsorbs on the mechan-
ical resonator, an abrupt resonance frequency downshift is observed
that is proportional to the ratio of the analyte mass to the device mass
with a proportionality constant that depends on the adsorption posi-
tion. The mass and adsorption position were decoupled by simultaneous
measurement of the ﬁrst two vibration modes of the resonator, a doubly
clamped nanobeam. Nanomechanical mass spectrometry has been
successfully applied for ‘weighting’ BSA (66 kDa), β-amylase (200 kDA)
and immunoglobulin M (960 kDa) in puriﬁed solutions. The mass re-
solution was of the order of 10 KDa, approximately. This resolution is
still very far from that achieved in conventional MS. Nanomechanical
mass spectrometry can readily achieve higher mass resolution
(∼10 Da) by miniaturizing the employed nanomechanical resonator.
However, the capture eﬃciency, that is inversely proportional to the
resonator area, rapidly degrades with miniaturization. It is expected
that this limitation will be overcome in the next years. Advances in
micro- nanofabrication technologies are mature enough to provide
highly dense two-dimensional arrays of nanomechanical resonators
(> 1000 devices) operating in parallel in order to increase the capture
eﬃciency without losing mass sensitivity [94,95].
3.2.4. Nanomechanical mass and stiﬀness spectrometry
Theoretical models had predicted that the stiﬀness of the analyte
inﬂuences on the resonance frequency variations recorded in nano-
mechanical spectrometers [17,85,87] (Fig. 9(a)). This eﬀect is parti-
cularly relevant when using ultrathin nanomechanical systems
(< 100 nm) or when the analyte size is comparable to the beam
thickness. In 2016, a custom-built nanomechanical spectrometer
proved the capability for resolving the mass and stiﬀness of analytes
landing on the surface of a microcantilever [96]. Electrospray ioniza-
tion was used to generate mostly desolvated charged species at ambient
pressure, and subsequently the charged species were guided to the
Fig. 8. Left: schematic representation of a nano-
mechanical sandwich immunoassay. (a) The micro-
cantilever functionalized with capture antibodies is
immersed in the human plasma sample to allow
speciﬁc binding of the sought protein. (b) The pro-
tein biomarker captured on the cantilever is speciﬁ-
cally linked to gold nanoparticles that carry detec-
tion antibodies. The diameter of the gold
nanoparticles can range from 50 to 100 nm. (c)
Example of PSA detection in human plasma (un-
published results of the authors). The resonance
frequency of the microcantilevers downshifts by an
amount that is proportional to the ratio between the
mass added by the nanoparticles and the micro-
cantilever mass. The results illustrate how this
technology can explore the deepest region of the
plasma proteome.
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microcantilever at low vacuum by pressure gradient through three
chambers with decreasing pressure. The proof of concept was demon-
strated with gold nanoparticles and bacteria E. coli. Fig. 9(b) shows the
abrupt jumps in the vibrational properties of the microcantilever as
individual bacterial cells land on the vibrating microcantilever. The
technique allows measurement in low vacuum, which makes that the
biological analyte arrive intact and near native conformation
(Fig. 9(c)). Numerical algorithms allow translation of the variations of
the resonance frequencies into the mass and stiﬀness of each bacteria
(Fig. 9(d)).
Nanomechanical spectrometry is still in its infancy and far from
implementation in proteomics. However, we foresee rapid develop-
ments in the next years that can place this technology close to the needs
in proteomics. The mass resolution is still very far from that obtained in
MS, although it can be readily improved to 100 Da with existing de-
vices. Mass spectrometry measures the mass-to-charge ratio of mole-
cular species from 100 Da to 100 kDa with extremely high accuracy. At
this level, mass spectrometry is unbeatable. However, its performance
largely degrades on the measurement of heavier species, such as intact
proteins and protein complexes. The application of MS in proteomics
requires of the fragmentation of the proteins into small peptides. The
MS and MS/MS patterns become diﬃcult to interpret and in addition,
the information on the biological processes such as protein–protein
interactions is lost. Experiments of nanomechanical spectrometry with
silicon nanowires (Fig. 6(b)) and inorganic adsorbates have demon-
strated the capability to simultaneously achieve high resolution in mass
and stiﬀness. Translation of these results to proteins imply identifying
proteins with a mass resolution of 1 kDa and detecting variation in the
Young’s modulus of the protein of 0.1% [72,73]. It is well-known that
subtle protein changes such as single mutations that may be un-
detectable by mass are manifested as biologically relevant mechanical
changes. Nanomechanical spectrometry could be applied for detecting
these modiﬁcations. Another virtue of nanomechanical spectrometry is
that the nanomechanical signature is insensitive to the charge of the
analyte, simplifying the analysis of the data [97]. The enormous
number of charge states obtained in MS produces complex spectra with
overlapping peaks that are often diﬃcult to interpret. Only time will tell
if advancements in nanomechanical spectrometry will be able to tackle
the acute problems in proteomics for the discovery of useful protein
biomarkers for early cancer detection. Meanwhile, a European initiative
involving several laboratories with multidisciplinary expertise has been
launched in order to achieve a nanomechanical spectrometer able to
identify harmful viruses by mass and stiﬀness from blood samples in
clinical setting (http://viruscanproject.eu/). If this project succeeds, we
Fig. 9. (a) Schematic depiction of an adsorbate on a cantilever vibrating at the resonance frequency of the second vibration mode. The stiﬀness of the adsorbate induces a positive shift of
the resonance frequency. Although the overall shift of the resonance frequency is negative, accurate quantiﬁcation of the mass of the adsorbate requires accounting for the stiﬀness eﬀect.
(b) Real-time record of the fractional shifts of the resonance frequencies of the ﬁrst four vibration modes of the microcantilever during bacteria adsorption. The shapes of the vibration
modes of the cantilever are shown in the insets. The time-correlated frequency jumps in the graphs correspond to adsorption events of single bacterial cells. (c) SEM image of an E. coli cell
on the microcantilever. The insets show closer views of the bacterium. (d) Nanomechanical ﬁngerprint of the E. coli cells corresponding to 189 adsorptions. Eeﬀ is the eﬀective stiﬀness of
E. coli cells.
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will soon witness the ﬁrst generation of nanomechanical spectrometers
for human proteomics.
4. Conclusions
Early cancer detection will be achieved once that we can identify
the protein biomarkers shed by the tumor to the bloodstream since its
inception. Proteomic technologies, mainly mass spectrometry and
multiplexed immunoassays, have rapidly developed during recent years
with improved limits of detection and multiplexing capability. They can
reliably explore the plasma proteome up to the ng/mL level, and in
some cases to the pg/mL level. Still, thousands of unidentiﬁed proteins
are expected to be discovered in the human plasma with major re-
ﬁnement of these proteomic technologies. However, access to the
deepest region of the proteome will require of new ultrasensitive
technologies capable of quantitating proteins in the plasma at con-
centrations several orders of magnitude lower than 1 pg/mL. This re-
gion of the plasma proteome is likely to contain speciﬁc protein bio-
markers for early cancer detection. Here we propose the development
of biological detectors based on nanomechanical systems for their in-
corporation into the technological arsenal of human proteomics. In
particular, we point out to two recent developments, nanomechanical
sandwich immunoassays and nanomechanical spectrometry. The ﬁrst
technique enables reproducible immunodetection of proteins at con-
centrations well below the pg/mL level, with a limit of detection on the
verge of 10 ag/mL. This technology can potentially detect low abun-
dance tumor-associated proteins at the very early stages of the tumor.
Its level of development enables its rapid integration into the protein
biomarker discovery pipeline. The second technique enables the iden-
tiﬁcation of individual proteins by two physical coordinates, the mass
and stiﬀness of the intact protein. Although still far from implementa-
tion in proteomics, it can easily beneﬁt from the already MS advanced
technologies for protein separation, nanoelectrospray ionization and
eﬃcient transport of protein ions in vacuum to the detector. We believe
that in the near future nanomechanical protein detectors will play a
fundamental role for deciphering the deepest region of the human
plasma proteome. Let us cross the ﬁngers for witnessing the discovery
of speciﬁc cancer biomarkers that can save millions of lives every year
by using a simple blood test.
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